Neoxanthin (Chloroplast Allenic Xanthophyll · Antiproliferative · Fucoxanthin Structural Analogue)

Compound	Neoxanthin (5’,6’-Epoxy-5,6-dihydrocarotenoid)
Chemical class	Terpenoid — Carotenoid / Xanthophyll (Allenic epoxy xanthophyll; chloroplast xanthophyll)
CAS	14660-91-4
Primary source	Green leafy vegetables (spinach, kale, broccoli) — major chloroplast xanthophyll alongside lutein and violaxanthin
Key applications	Antioxidant; antiproliferative (via fucoxanthinol-type metabolite neoxanthinol); chloroplast light-harvesting; availability on request
Claim strength	Moderate (preclinical)
Typical form	Spinach/leafy green extract; neoxanthin-enriched green leaf extract; neoxanthin isolate (research grade)
Buy from Herbuno	Request availability and bulk pricing →

Name origin: Neo- (Greek: new) + xanthin (yellow pigment) — reflecting that it was a newly discovered yellow pigment. Neoxanthin is an allenic epoxy xanthophyll — it contains both an allenic bond (C=C=C) and a 5’,6’-epoxide, structural features it shares with fucoxanthin (the marine carotenoid with powerful fat-metabolism activity, built SM20). This structural similarity to fucoxanthin is pharmacologically significant: neoxanthin is metabolised in the gut to neoxanthinol — a metabolite structurally similar to fucoxanthinol (fucoxanthin’s active metabolite responsible for WAT browning). This metabolic relationship has generated research interest in neoxanthin as a potentially accessible land-plant source of fucoxanthin-like metabolites. Chloroplast significance: Neoxanthin is a major constituent of the light-harvesting complex II (LHCII) of higher plant chloroplasts — involved in light collection and photoprotection (non-photochemical quenching of excess light energy). It is present in all higher plants that perform oxygenic photosynthesis. Every green leaf contains neoxanthin. Research trajectory: Neoxanthin research was relatively dormant until the fucoxanthin-fat metabolism discovery revived interest in allenic xanthophylls. Studies show neoxanthin has antiproliferative activity in prostate and colon cancer cell lines, potentially mediated via neoxanthinol. Commercial source: Spinach powder from Herbuno delivers neoxanthin as a component of the green xanthophyll fraction; isolated neoxanthin is not commercially established.

---

Evidence for Neoxanthin Applications

Antiproliferative via neoxanthinol: Neoxanthin is metabolised in the GI tract to neoxanthinol (by esterase-mediated cleavage of the allenic bond) — a metabolite with structural and biological similarity to fucoxanthinol. Studies show neoxanthinol induces apoptosis in human prostate cancer (PC-3) and colon cancer cells via mitochondrial pathway activation. The biological relevance of dietary neoxanthin as a neoxanthinol source is supported by in vitro digestion studies showing neoxanthinol formation from spinach-derived neoxanthin. Claim strength: Moderate (preclinical; metabolite pharmacology).

Antioxidant: Neoxanthin’s allenic epoxy structure confers potent singlet oxygen quenching activity — at the same level or above that of lutein or zeaxanthin per molecule. In plant LHCII, neoxanthin functions specifically as a triplet chlorophyll quencher, protecting against photooxidative damage. Claim strength: Moderate.

Potential fat metabolism (fucoxanthinol-type): If neoxanthinol reaches adipose tissue at meaningful concentrations after dietary neoxanthin, it may share fucoxanthinol’s UCP1-inducing activity in white adipose tissue. This is a hypothesis based on structural similarity — not yet tested in controlled studies. Claim strength: Emerging (structural hypothesis; no direct human or animal data).

---

Frequently Asked Questions — Neoxanthin

Is neoxanthin the same as fucoxanthin?
Structurally related but not identical. Both are allenic xanthophylls with epoxide groups — but neoxanthin is a land-plant carotenoid with slightly different chain length and stereochemistry compared to fucoxanthin (a marine algal carotenoid). Their active metabolites (neoxanthinol and fucoxanthinol respectively) are similarly related — both are allenic carotenol metabolites. The key pharmacological difference: fucoxanthinol has robust evidence for UCP1 induction and fat metabolism (from controlled human trials); neoxanthinol’s equivalent effects are preclinical hypotheses based on structural similarity.

How much neoxanthin is in spinach?
Spinach is one of the richest plant sources of neoxanthin — approximately 5–8 mg/100g fresh weight, compared to 5–11 mg/100g for lutein and zeaxanthin combined. This means a typical 100g serving of spinach provides meaningful amounts of neoxanthin alongside other xanthophylls. The bioavailability from cooked spinach (with fat) is significantly higher than raw spinach — consistent with all xanthophyll carotenoids. Other rich sources: kale, broccoli, peas, green beans.

Does cooking affect neoxanthin stability?
Neoxanthin is more thermolabile than lutein or beta-carotene — the allenic bond and epoxide are more susceptible to isomerisation and thermal degradation than the polyene chain of simpler carotenoids. Studies show 15–30% neoxanthin degradation during boiling compared to <10% for lutein under the same conditions. Light and oxygen exposure also degrade neoxanthin more rapidly than lutein. For maximum neoxanthin preservation: short steaming vs boiling; dark storage; consume soon after preparation.

Can neoxanthin supplements replace lutein for eye health?
No — lutein and zeaxanthin are the specific macular carotenoids accumulating in the human retinal macula, providing photoprotection against blue light and age-related macular degeneration (AMD). Neoxanthin does not accumulate selectively in the macula and does not have the same specific eye-protective evidence base as lutein/zeaxanthin. AREDS2 (the definitive AMD supplementation trial) used lutein and zeaxanthin, not neoxanthin. Neoxanthin’s systemic antioxidant and antiproliferative properties are independent of the macular lutein/zeaxanthin specific applications.

Related compounds: Fucoxanthin, Lutein, Alpha-Carotene, Capsanthin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery